Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir

A case report

Shengbo Fang, MD\textsuperscript{a,*}, Lingli Qi, MD\textsuperscript{a}, Na Zhou, PhD\textsuperscript{b}, Chunyan Li, PhD\textsuperscript{a,*}

Abstract

Rationale: Oseltamivir-induced alimentary tract hemorrhage and liver injury are rarely reported in children and adult individuals. In this study, we described the clinical features and outcomes of oseltamivir-induced alimentary tract hemorrhage and liver injury in a child.

Patient concerns: Here, we present a case of a 6-year-old Asian boy with hematemesis and elevated alanine aminotransferase (ALT) (80 U/L) and aspartate aminotransferase (AST) (69 U/L) levels on day 2 of oseltamivir administration. The presence of alimentary tract hemorrhage and liver injury was diagnosed. The ALT level reached 1931.3 U/L, accompanied by an increase in total bilirubin (TBIL) to 53.3 μmol/L on day 15 after oseltamivir administration. Additional tests were performed to determine the presence of viruses that can cause hepatitis and autoantibodies, and the results from these tests were all negative.

Diagnosis: Drug-induced liver injury was considered.

Interventions: This patient was treated with compound glycyrrhizin and reduced glutathione and glucocorticoid.

Outcomes: The liver enzymes recovered within 6 weeks without any symptoms of liver-related diseases after treatment with glucocorticoid. This treatment therefore helps reduce ALT and TBIL levels and protects the liver from further injury.

Lessons: Oral oseltamivir is widely used to treat influenza and the adverse effects of this drug were mostly mild. However, clinicians should always be alert for oseltamivir-induced alimentary tract hemorrhage and liver injury when prescribing oseltamivir for children.

Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, CMV = cytomegalovirus, DILI = drug-induced liver injury, EBV = Epstein–Barr virus, HIV = human immunodeficiency virus, LKM = liver–kidney microsomes antibody, RUCAM = Roussel Uclaf Causality Assessment Method, SLA/LP = soluble liver antigen antibody/hepatopancreatic antigen antibody, TBIL = total bilirubin.

Keywords: alimentary tract hemorrhage, drug-induced liver injury, oseltamivir

1. Introduction

Influenza is a vital contributing cause of hospitalization and mortality in children aged <5 years.\textsuperscript{[1]} Oseltamivir is a neuraminidase inhibitor that was licensed by the US Food and Drug Administration (FDA) in 1999 to treat influenza. In the nearly 2 decades, the most commonly reported adverse effects of oseltamivir were nausea and vomiting\textsuperscript{[2,3]} whereas the severe or rare adverse effects include psychiatric manifestations,\textsuperscript{[4–8]} tongue swelling,\textsuperscript{[9]} enterorrhagia,\textsuperscript{[10–13]} dyskinesia,\textsuperscript{[14]} bradycardia,\textsuperscript{[15]} glaucoma, transient myopia,\textsuperscript{[16]} and Stevens–Johnson syndrome.\textsuperscript{[17]} However, alimentary tract hemorrhage and liver injury after oseltamivir treatment have been rarely reported.

1.1. Consent statement

Informed consent was obtained from the patients for the publication of this study.

2. Case report

A 6-year-old Asian boy was admitted into hospital due to severe liver injury. The boy had no prior history of diseases, surgery, and medication. Two weeks ago, the boy had a fever (39.5°C) and was given ibuprofen (0.1 g, twice to 3 times daily). However, the boy still had frequent fever and thus was taken to local hospital and received an empirical treatment of oseltamivir for influenza infection. According to the medication package insert, the boy should take a 5-day course of 60 mg of oseltamivir twice a day. On the second dose of oseltamivir, the boy began to experience hematemesis (approximately 5 ml). The liver function of the boy became abnormal with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values of 80 U/L (reference range: 9–50 U/L) and 69 U/L (reference range: 15–40 U/L), respectively. Oseltamivir treatment was suspended due to these circumstances. Three days before admission, ALT and AST...
continued to increase to more than a dozen times. On the 2nd day in hospital, ALT increased to the peak of 1931.5 U/L with total bilirubin (TBIL) increasing to 53.3 μmol/L (reference range: 6.0–30.0 μmol/L). In the course of illness, the boy complained of fatigue and his skin and sclera were slightly yellow. Imaging examination was performed, and the test exhibited negative results. Different tests were performed to determine the presence of the following different pathogens: antibodies to hepatitis A, B, C viruses; cytomegalovirus (CMV); Epstein–Barr virus (EBV); treponema pallidum; tuberculosis bacillus, and human immunodeficiency virus (HIV). Furthermore, tests for autoantibodies such as antinuclear antibody (ANA), antismooth muscle antibody (ASM), antimitochondrial antigen antibody (AMA), liver-kidney microsomes antibody (LKM), soluble liver antigen antibody/hepatopancreatic antigen antibody (SLA/LP) were also performed and the results from all these tests were negative. The thyroid function of the boy showed no abnormalities, and the levels of ceruloplasmin were also normal. The boy recovered by treatment with hepatic protector such as compound glycyrrhizin, reduced glutathione, and glucocorticoid in 12 days. The boy’s liver function level returned to normal after 2 weeks of discharge. The laboratory data of his liver function before and after admission are summarized in Table 1.

3. Discussion

The 6-year-old Asian boy first received oseltamivir. Although ibuprofen was previously administered to him before the alimentary tract hemorrhage and liver injury, the gastrointestinal injury due to ibuprofen was dose-related. A meta-analysis of 8 randomized, double-blind placebo-controlled trials in patients aged 2–12 years who were exposed to multiple Over The Counter doses of ibuprofen (800 or 1200 mg/day for 1–10 days) was found to have no specific gastrointestinal adverse events rate in the ibuprofen and placebo group. For hepatic safety, ibuprofen had the lowest incidence rate (at 1.6/100,000) of inducing liver injury among nonsteroidal anti-inflammatory drugs. Liver injury would more likely to occur by taking ibuprofen for 6 to 9 times and combined with other potential hepatotoxicity medicines. In this case, the boy weighing 27.5 kg only took 0.1 g of ibuprofen (3.64 mg/kg) 3 times. Moreover, the boy took ibuprofen before and has not observed any adverse effect. Therefore, ibuprofen is less likely to cause alimentary tract hemorrhage and liver injury. According to Roussel Uclaf Causality Assessment Method (RUCAM), a well-established tool commonly used to quantitatively assess causality in cases of suspected drug-induced liver injury (DILI), oseltamivir had a score of 7, which indicated a probable relationship of oseltamivir and liver injury. Thus, the liver injury in this case was probably caused by oseltamivir.

As inactive precursor drugs, oseltamivir phosphate can be converted into oseltamivir carboxylate by liver esterase. Oseltamivir carboxylate plays an important role in inhibiting influenza A and B viral neuraminidase. Although the adverse effects caused by oseltamivir were mostly mild, sudden onset-type reactions, including hypothermia, abnormal behavior, and sudden death, have been reported. Delayed onset-type reactions were also reported including reduction of antibody production, renal disorders, hyperglycemias, psychiatric disorders, and QT prolongation. Other adverse reactions were presented with pneumonia, wheezing, gastrointestinal bleeding, and hepatic and/or hematological impairment. The mechanism of action by oseltamivir in gastrointestinal bleeding and hepatic impairment is still unknown. Yang et al. found that the liver esterase activity of age < 1 year and immature animals (including humans) was lower than the mature individuals; this phenomenon may increase the blood concentration of nonactivated oseltamivir giving rise to toxic effects.

DILI is an uncommon but important cause of liver disease that can arise after exposure to various kinds of chemical drugs, biological agents, and herbal and dietary supplements. The annual incidence of DILI is about 14 to 19/100,000 inhabitants. This study was the first case of oseltamivir-induced liver injury in children. The boy developed liver injury after 2 doses with elevated levels of hepatic aminotransferase and bilirubin. Without permission from the boy’s parents, we were not able to conduct liver biopsy test to investigate the changes in liver pathology. Given that no guideline or data on how to control DILI in children have been established, early recognition and withdrawal of the offending drug are some of the most important things that can be performed. Although oral oseltamivir is widely used to treat influenza and the adverse effects were mostly mild, clinicians should always be alert for oseltamivir induced liver injury when prescribing oseltamivir for children, especially when used empirically. In addition, the precise mechanism of oseltamivir causing liver injury is still unknown. Whether or not other neuraminidase inhibitors can also cause liver injury needs further investigation.

Author contributions

Investigation: Na Zhou.

Resources: Lingli Qi, Chunyan Li.

Writing - original draft: Shengbo Fang.

Writing - review & editing: Shengbo Fang.

References

[1] Lafond KE, Nair H, Rasooly MH, et al. Global role and burden of influenza in pediatric respiratory hospitalizations, 1982-2012: a systematic analysis. PLoS Med 2016;13:e1001977.
[2] Malosh RE, Martin ET, Heikkinen T, et al. Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis 2018; 66:1492–500.

[3] He CH, Liu CY, Lin GY, et al. Efficacy and safety of oseltamivir in children with suspected influenza: a multicenter randomized open-label trial. Zhonghua Er Ke Za Zhi 2017;55:462–7.

[4] Guisado-Macías JA, Rodríguez FF, Méndez-Sánchez F, Bolívar-Peralvarez M. Oseltamivir-related psychiatric manifestations. Actas Esp Psiquiatr 2012;40:46–8.

[5] Kohen I. Oseltamivir-induced delirium in a geriatric patient. Int J Geriatr Psychiatry 2007;22:935–6.

[6] Ho LN, Chung JP, Choy KL. Oseltamivir-induced mania in a patient with H1N1. Am J Psychiatry 2010;167:330.

[7] Lan CC, Liu CC, Chen YS. Acute exacerbation of psychiatric symptoms during influenza treatment with oseltamivir in chronic schizophrenia. J Chin Med Assoc 2013;78:374–6.

[8] Morimoto K, Nagaoka K, Nagai A, et al. Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report. BMC Neurol 2013;13:130.

[9] Kalsi T, Stevenson J, Wade P, et al. Tongue swelling in association with oseltamivir (Tamiflu). BMJ Case Rep 2011: pii: bcr0620114396.

[10] Beraldi-Magalhaes F, Batista V, Cordeiro-Santos M. Oseltamivir as a cause of acute enterorrhagia. Braz J Infect Dis 2016;20:521.

[11] Chen YH, Lai HJ. Acute hemorrhagic colitis after oral administration of oseltamivir for influenza. Gastrointest Endosc 2013;77:976.

[12] Matsushita M, Nishihara H, Nishiyama R, et al. Acute hemorrhagic colitis associated with oral administration of oseltamivir for the treatment of influenza A. J Infect Chemother 2007;13:267–9.

[13] Nakagawa Y, Nagai T, Okawara H, et al. Acute hemorrhagic colitis induced by the oral administration of oseltamivir used for influenza A treatment. Endoscopy 2011;43(suppl 2 UCTN):E261.

[14] Kadowaki T, Komagamine T, Suzuki K, et al. Oseltamivir-induced dyskinesia in Parkinson’s disease. Parkinsonism Relat Disord 2011;17:133–4.

[15] Karplus R, Sanset S, Zaidenstein R, et al. Suspected oseltamivir-induced bradycardia. Int J Infect Dis 2010;14(suppl 3):e374–5.

[16] Lee JW, Lee JE, Choi HY, et al. Oseltamivir (Tamiflu)-induced bilateral acute angle-closure glaucoma and transient myopia. Indian J Ophthalmol 2014;62:1165–7.

[17] Smith EV, Pynn MC, Blackford S, et al. Stevens-Johnson syndrome secondary to oseltamivir (Tamiflu). Br J Gen Pract 2010;60:133–4.

[18] Garcia Rodriguez LA, Williams R, Derby LE, et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994;154:311–6.

[19] Perez Gutthann S, Garcia Rodriguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology (Cambridge, Mass) 1993;4:496–501.

[20] Hama R. The mechanisms of delayed onset type adverse reactions to oseltamivir. Infect Dis (Lond) 2016;48:651–60.

[21] Hama R, Bennett CL. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurol Scand 2017;135:148–60.

[22] Kellstein DE, Waksman JA, Furey SA, et al. The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. J Clin Pharmacol 1999;39:320–32.

[23] Moore N, Scheiman JM. Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesics. Postgrad Med 2018;130:188–99.

[24] Yang D, Pearce RE, Wang X, et al. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 2009;77:238–47.

[25] Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int 2018;[Epub ahead of print].